Spots Global Cancer Trial Database for celecoxib
Every month we try and update this database with for celecoxib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | NCT02030964 | Neuroblastoma | DFMO Celecoxib Cyclophosphamid... Topotecan | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | NCT01220973 | Prostate Cancer | atorvastatin ca... celecoxib laboratory biom... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma | NCT00603759 | Head and Neck C... | celecoxib placebo | 20 Years - | Tehran University of Medical Sciences | |
| An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors | NCT03864575 | Metastatic Canc... | Celecoxib 400 m... | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Chemoprevention of Oral Premalignant Lesions | NCT00036283 | Precancerous Co... | Celecoxib | 18 Years - | Pfizer | |
| Chemoprevention of Oral Premalignant Lesions | NCT00036283 | Precancerous Co... | Celecoxib | 18 Years - | Pfizer | |
| Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus | NCT00005878 | Esophageal Canc... | celecoxib | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis | NCT00808743 | Familial Adenom... Duodenal Neopla... Duodenal Polyps | Celecoxib Ursodeoxycholic... Placebo | 18 Years - 70 Years | Radboud University Medical Center | |
| Celecoxib as a Chemopreventive Agent in Current and Former Smokers | NCT00981201 | Smoking Prevention | Celecoxib Celecoxib Placebo Placebo | 18 Years - 74 Years | M.D. Anderson Cancer Center | |
| The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma | NCT02537925 | Nasopharyngeal ... | Celecoxib Nedaplatin Concurrent Radi... | 18 Years - 60 Years | Nanning Second People's Hospital | |
| Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | NCT01341496 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Epigenetically ... Cyclophosphamid... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
| Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer | NCT00520845 | Lung Cancer | celecoxib Docetaxel pemetrexed diso... laboratory biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy | NCT00300729 | Non-Small Cell ... | Celecoxib Placebo | 18 Years - | University Hospital, Linkoeping | |
| Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | NCT00525096 | Metastatic Brea... | placebo Celecoxib Exemestane | 18 Years - | ARCAGY/ GINECO GROUP | |
| Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers | NCT00001693 | Colorectal Neop... Hereditary Nonp... | Celecoxib (SC-5... | - | National Institutes of Health Clinical Center (CC) | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer | NCT00068653 | Lung Cancer | Celecoxib ZD1839 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer | NCT00023660 | Cervical Cancer | celecoxib cisplatin fluorouracil brachytherapy radiation thera... | 18 Years - 85 Years | Radiation Therapy Oncology Group | |
| A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | NCT00215345 | Prostate Cancer | Taxotere Celecoxib | 18 Years - | Department of Veterans Affairs, New Jersey | |
| Celecoxib and Erlotinib in Treating Patients With Liver Cancer | NCT00293436 | Liver Cancer | celecoxib erlotinib hydro... adjuvant therap... | 18 Years - | University of California, San Francisco | |
| Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps | NCT00005094 | Colon Cancer Rectal Cancer | celecoxib placebo | 30 Years - | National Cancer Institute (NCI) | |
| Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | NCT00073970 | Prostate Cancer | celecoxib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer | NCT00295035 | Colon Neoplasm | CELECOXIB CURCUMIN | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity | NCT00953849 | Mouth Neoplasms | Celecoxib Calcitriol Celecoxib plus ... | 18 Years - 85 Years | VA Office of Research and Development | |
| Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer | NCT02885974 | Bladder Cancer | Celecoxib Gemcitabine Cisplatin | 18 Years - | Baylor College of Medicine | |
| Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer | NCT00087256 | Colorectal Canc... | Celecoxib placebo | 18 Years - | NSABP Foundation Inc | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer | NCT00176813 | Pancreatic Canc... | Gemcitabine Cisplatin Celecoxib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer | NCT00165451 | Neoplasms | Thalidomide Celecoxib Etoposide Cyclophosphamid... | - 21 Years | Dana-Farber Cancer Institute | |
| Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer | NCT00527982 | Head and Neck C... Lung Cancer | Celecoxib | 18 Years - | M.D. Anderson Cancer Center | |
| Celecoxib in Treating Patients With Precancerous Lesions of the Mouth | NCT00014404 | Head and Neck C... | celecoxib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | NCT01341496 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Epigenetically ... Cyclophosphamid... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | NCT00357500 | Central Nervous... Leukemia Lymphoma Neuroblastoma Sarcoma Unspecified Chi... | celecoxib cyclophosphamid... etoposide fenofibrate thalidomide | - 21 Years | Dana-Farber Cancer Institute | |
| Cox-2 Inhibition in Radiation-induced Oral Mucositis | NCT00698204 | Oral Mucositis | celecoxib placebo | 18 Years - 75 Years | UConn Health | |
| An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors | NCT03864575 | Metastatic Canc... | Celecoxib 400 m... | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | NCT00037817 | Advanced Esopha... Primary Small C... Non-Small-Cell ... Pleural Mesothe... Cancers of Non-... | Decitabine Depsipeptide Celecoxib | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Celecoxib in Preventing Skin Cancer | NCT00025051 | Non-melanomatou... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... growth factor a... | 20 Years - 60 Years | National Cancer Institute (NCI) | |
| For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | NCT00037180 | Neoplasm Metast... Colorectal Neop... | Celecoxib Irinotecan 5-fluorouracil Leucovorin | 18 Years - | Pfizer | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | NCT00072540 | Stage 0 Cervica... High-grade Squa... | celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a... | 18 Years - | SWOG Cancer Research Network | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients | NCT00211952 | Non-Small Cell ... | celecoxib | 18 Years - | Medical University of Gdansk | |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT00499655 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | erlotinib hydro... celecoxib placebo laboratory biom... immunohistochem... fluorescence in... mutation analys... protein express... gene expression... | 18 Years - | City of Hope Medical Center | |
| Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses | NCT00027976 | Precancerous Co... | celecoxib Placebo | 18 Years - | University of Alabama at Birmingham | |
| Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer | NCT00177853 | Pancreatic Canc... | celecoxib irinotecan concurrent radi... | 18 Years - | University of Pittsburgh | |
| For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | NCT00037180 | Neoplasm Metast... Colorectal Neop... | Celecoxib Irinotecan 5-fluorouracil Leucovorin | 18 Years - | Pfizer | |
| Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | NCT00081224 | Colorectal Canc... | capecitabine celecoxib radiation thera... surgery | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer | NCT00551889 | Unspecified Adu... | celecoxib cyclophosphamid... laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women | NCT00056082 | Breast Cancer | celecoxib | 18 Years - 55 Years | University of Kansas Medical Center | |
| Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) | NCT00585312 | Adenomatous Pol... | Celecoxib Placebo | 10 Years - 17 Years | Pfizer | |
| Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies | NCT01705106 | Unspecified Adu... | capecitabine celecoxib pharmacological... laboratory biom... pharmacogenomic... | 18 Years - | University of Chicago | |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | NCT02054104 | Thoracic Sarcom... Thorasic Cancer... Cancers of Non-... Sarcoma Melanoma | H1299 cell lysa... Cyclophosphamid... Celecoxib Iscomatrix adju... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cox-2 Inhibition in Radiation-induced Oral Mucositis | NCT00698204 | Oral Mucositis | celecoxib placebo | 18 Years - 75 Years | UConn Health | |
| Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | NCT00073970 | Prostate Cancer | celecoxib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers | NCT05438303 | Healthy Volunte... | AZD9833 Midazolam Omeprazole Dabigatran Etex... Celecoxib | 50 Years - 70 Years | AstraZeneca | |
| Pre-Prostatectomy Celecoxib or Placebo | NCT02840162 | Adenocarcinoma ... Prostate Cancer | Celecoxib Placebo | 18 Years - | OHSU Knight Cancer Institute | |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | NCT04469530 | Solid Tumor | Sirolimus Cyclophosphamid... Etoposide Celecoxib | 1 Year - 30 Years | Emory University | |
| A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers | NCT00231829 | Uterine Cancer | Celecoxib | 18 Years - | Montefiore Medical Center | |
| Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | NCT00665457 | Breast Cancer | filgrastim capecitabine celecoxib cyclophosphamid... docetaxel doxorubicin hyd... gene expression... polymorphism an... protein express... reverse transcr... imaging biomark... immunohistochem... laboratory biom... pharmacogenomic... dynamic contras... needle biopsy neoadjuvant the... radiomammograph... ultrasound imag... | 19 Years - 120 Years | University of Nebraska | |
| Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer | NCT00045591 | Breast Cancer | celecoxib Celecoxib | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer | NCT01284504 | Colorectal Canc... Colon Cancer | Celecoxib placebo | 18 Years - 75 Years | Stanford University | |
| Window of Opportunity Study Targeting the Inflammatory Milieu | NCT01881048 | Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Omega-3 fatty a... Celecoxib | 18 Years - 50 Years | University of Colorado, Denver | |
| Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00072072 | Lung Cancer | celecoxib erlotinib hydro... | 21 Years - | National Cancer Institute (NCI) | |
| Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | NCT01313429 | Sarcoma Melanoma Epithelial Mali... Pleural Maligna... | Cyclophosphamid... Allogenic tumor... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Low Dose Metronomic Poly-chemotherapy for Metastatic CRC | NCT02280694 | Colorectal Canc... | Capecitabine Cyclophosphamid... Methotrexate Celecoxib | 18 Years - 85 Years | HaEmek Medical Center, Israel | |
| Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery | NCT04176419 | Postoperative P... Opioid Consumpt... | Ketamine Placebo Ketamin... Lidocaine Placebo Lidocai... Acetaminophen Placebo Acetami... Gabapentin Placebo Gabapen... Celecoxib Placebo Celecox... | 18 Years - | Case Comprehensive Cancer Center | |
| Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers | NCT05438303 | Healthy Volunte... | AZD9833 Midazolam Omeprazole Dabigatran Etex... Celecoxib | 50 Years - 70 Years | AstraZeneca | |
| Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | NCT00499655 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | erlotinib hydro... celecoxib placebo laboratory biom... immunohistochem... fluorescence in... mutation analys... protein express... gene expression... | 18 Years - | City of Hope Medical Center | |
| Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | NCT00064181 | Colorectal Canc... | FOLFIRI regimen capecitabine celecoxib fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00101062 | Breast Cancer | celecoxib letrozole | 18 Years - | Rutgers, The State University of New Jersey | |
| Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers | NCT00020878 | Lung Cancer | celecoxib | 45 Years - | Jonsson Comprehensive Cancer Center | |
| Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis | NCT00033371 | Colorectal Canc... Familial Adenom... | Celecoxib Placebo eflornithine Laboratory biom... Questionnaire a... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme | NCT00112502 | Brain and Centr... Glioblastoma Mu... | Celecoxib Isotretinoin Temozolomide Thalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer | NCT01284504 | Colorectal Canc... Colon Cancer | Celecoxib placebo | 18 Years - 75 Years | Stanford University | |
| Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT00030420 | Lung Cancer | Celecoxib Docetaxel | 18 Years - | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
